Tvardi Therapeutics, Inc. (TVRD) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 2.01 |
| Open | 2.16 |
| Day High | 3.86 |
| Day Low | 2.07 |
| 52-Week High | 43.65 |
| 52-Week Low | 1.5 |
| Volume | 70.45M |
| Average Volume | 162,172 |
| Market Cap | 29.08M |
| PE | -1 |
| EPS | -3.1 |
| Moving Average 50 Days | 3.08 |
| Moving Average 200 Days | 6.95 |
| Change | 1.09 |
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 12, 2026 1:00 PM GMT
HOUSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 08, 2026 9:05 PM GMT
Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium PresentationHOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights
GlobeNewswire Inc.
Jan 08, 2026 1:00 PM GMT
Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the placebo group Topline healthy volunteer data from Phase 1 study of next-generation STAT3 inhibitor, TTI-